Compare ALNT & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALNT | XERS |
|---|---|---|
| Founded | 1962 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 1995 | 2021 |
| Metric | ALNT | XERS |
|---|---|---|
| Price | $70.37 | $6.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $64.50 | $10.83 |
| AVG Volume (30 Days) | 149.6K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.17% | N/A |
| EPS Growth | 67.09 | ★ 100.00 |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $554,478,000.00 | $49,590,000.00 |
| Revenue This Year | $7.53 | $34.37 |
| Revenue Next Year | $6.64 | $22.83 |
| P/E Ratio | $53.38 | ★ N/A |
| Revenue Growth | 4.62 | ★ 142.67 |
| 52 Week Low | $20.10 | $3.95 |
| 52 Week High | $72.89 | $10.08 |
| Indicator | ALNT | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 59.28 | 55.84 |
| Support Level | $55.21 | $5.76 |
| Resistance Level | N/A | $7.21 |
| Average True Range (ATR) | 3.02 | 0.24 |
| MACD | 1.06 | 0.08 |
| Stochastic Oscillator | 83.08 | 86.80 |
Allient Inc, formerly Allied Motion Technologies Inc designs, manufactures, and sells precision and specialty controlled motion components and systems. The firm mainly caters to the Industrial, Vehicle, Aerospace & Defense, and Medical sectors. It mainly operates and sells across the United States, Canada, South America, Europe, and Asia. Its products and solutions include nano precision positioning systems, servo control systems, motion controllers, digital servo amplifiers and drives, brushless servo, torque, and coreless motors, brush motors, integrated motor drives, gear motors, gearing, incremental and absolute optical encoders, active (electronic) and passive (magnetic) filters for power quality and harmonic issues.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.